

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-4 (cancelled)

Claim 5 (currently amended): A process for the purification of one or more antibodies from a liquid, comprising:

contacting said liquid in a first step, which is a capture step, with a first chromatography resin including a support to which multi-modal ligands have been immobilised to adsorb the antibodies to the resin, wherein each multi-modal ligand includes at least one cation-exchanging group and at least one aromatic or heteroaromatic ring system;

adding an eluent to release the antibodies from the resin; and

contacting the eluate so obtained with a second chromatography resin;
wherein the liquid contacted with the first chromatography resin is a cell culture liquid or a fermentation broth and host cell residues are removed in the first step.

Claims 6-7 (cancelled)

Claim 8 (previously presented): The process of claim 5, wherein the cation-exchanging group of the multi-modal ligands is a weak cation exchanger.

Claim 9 (previously presented): The process of claim 5, wherein the second chromatography resin is selected from the group consisting of ion exchange chromatography; hydrophobic interaction chromatography (HIC); immobilised metal affinity chromatography (IMAC); and affinity chromatography.

Claim 10 (previously presented): The process of claim 9, wherein the second chromatography resin is ion exchange chromatography.

Claim 11 (previously presented): The process of claim 5, wherein the second chromatography resin is anion exchange chromatography.

Claim 12 (previously presented): The process of claim 5, wherein the second chromatography resin is multimodal anion exchange chromatography.

Claim 13 (previously presented): The process of claim 5, wherein antibodies are recovered from the flow-through of the second chromatography resin.

Claim 14 (previously presented): The process of claim 5, wherein antibodies and/or impurities are eluted from the second chromatography resin.

Claim 15 (previously presented): The process of claim 5, wherein the antibodies are monoclonal antibodies.

Claim 16 (previously presented): The process of claim 5, wherein the antibodies are polyclonal antibodies.

Claim 17 (cancelled)

Claim 18 (currently amended): A process for the purification of one or more antibodies from a liquid, comprising:

contacting said liquid in a first step, which is a capture step, with a first chromatography resin to adsorb the antibodies to ligands, which resin is multimodal and comprises a support to which the ligands have been immobilised, wherein the resin includes cation-exchanging groups and aromatic or heteroaromatic ring systems present on different ligands;

adding an eluent to release the antibodies from the resin; and

contacting the eluate so obtained with a second chromatography resin;
wherein the liquid contacted with the first chromatography resin is a cell culture liquid or a fermentation broth and host cell residues are removed in the first step.

Claims 19-30 (cancelled)